Iowa's Center for Agriculture Safety and Health Annual Report, 2005

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2006

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2007

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2009

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2010

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2011

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2012

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Iowa's Center for Agriculture Safety and Health Annual Report, 2013

I-CASH is to enhance the health and safety of Iowa's agricultural community by establishing and coordinating prevention and education programs. This annual report gives information about a variety of areas that participate in I-CASH

Automatic filtering and substantiation of drug safety signals

Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great importance to unravel the molecular mechanisms by which an adverse drug reaction can be potentially elicited. These mechanisms can be investigated by placing the pharmaco-epidemiologically detected adverse drug reaction in an information-rich context and by exploiting all currently available biomedical knowledge to substantiate it. We present a computational framework for the biological annotation of potential adverse drug reactions. First, the proposed framework investigates previous evidences on the drug-event association in the context of biomedical literature (signal filtering). Then, it seeks to provide a biological explanation (signal substantiation) by exploring mechanistic connections that might explain why a drug produces a specific adverse reaction. The mechanistic connections include the activity of the drug, related compounds and drug metabolites on protein targets, the association of protein targets to clinical events, and the annotation of proteins (both protein targets and proteins associated with clinical events) to biological pathways. Hence, the workflows for signal filtering and substantiation integrate modules for literature and database mining, in silico drug-target profiling, and analyses based on gene-disease networks and biological pathways. Application examples of these workflows carried out on selected cases of drug safety signals are discussed. The methodology and workflows presented offer a novel approach to explore the molecular mechanisms underlying adverse drug reactions

Safety & You, September 2011

Iowa State University Police Department annually prepares and distributes “Safety & You” to all students, faculty, staff, as well as potential students and employees. Campus crime, arrest and referral statistics include those reported to the ISU Police, designated campus officials (including, but not limited to, Department of Residence, Dean of Students Office, athletic coaches, and advisors to student organizations), Ames Police and the Story County Sheriff’s Office. The ISU Counseling and Thielen Student Health Centers are exempted by patient confidentiality laws from disclosing reported information. Iowa State University does not have a voluntary confidential procedure for reporting crimes to law enforcement

Safety & You, September 2012

Iowa State University Police Department annually prepares and distributes “Safety & You” to all students, faculty, staff, as well as potential students and employees. Campus crime, arrest and referral statistics include those reported to the ISU Police, designated campus officials (including, but not limited to, Department of Residence, Dean of Students Office, athletic coaches, and advisors to student organizations), Ames Police and the Story County Sheriff’s Office. The ISU Counseling and Thielen Student Health Centers are exempted by patient confidentiality laws from disclosing reported information. Iowa State University does not have a voluntary confidential procedure for reporting crimes to law enforcement

Safety & You, September 2013

Iowa State University Police Department annually prepares and distributes “Safety & You” to all students, faculty, staff, as well as potential students and employees. Campus crime, arrest and referral statistics include those reported to the ISU Police, designated campus officials (including, but not limited to, Department of Residence, Dean of Students Office, athletic coaches, and advisors to student organizations), Ames Police and the Story County Sheriff’s Office. The ISU Counseling and Thielen Student Health Centers are exempted by patient confidentiality laws from disclosing reported information. Iowa State University does not have a voluntary confidential procedure for reporting crimes to law enforcement

Safety & You, September 2014

Iowa State University Police Department annually prepares and distributes “Safety & You” to all students, faculty, staff, as well as potential students and employees. Campus crime, arrest and referral statistics include those reported to the ISU Police, designated campus officials (including, but not limited to, Department of Residence, Dean of Students Office, athletic coaches, and advisors to student organizations), Ames Police and the Story County Sheriff’s Office. The ISU Counseling and Thielen Student Health Centers are exempted by patient confidentiality laws from disclosing reported information. Iowa State University does not have a voluntary confidential procedure for reporting crimes to law enforcement

Lapatax: Safety profile of neoadjuvant lapatinib combined with docetaxel in Her 2/neu overexpressing breast cancer - EORTC protocol 10054

Objective: To assess the safety/tolerability of the combination lapatinib (L) and docetaxel (D) in patients with Her 2/neu overexpressing breast cancer (BC). This study is important as it will define how to deliver lapatinib with taxotere, a highly active drug in breast cancer. Patients and Methods: Female patients (pts) with locally advanced, inflammatory or large operable BC were treated with escalating doses of L from 1000 to 1250 mg/day, in combination with D given IV every 21 days at doses ranging from 75 to 100 mg/m2 for 4 cycles. At least 3 pts were treated at each dose level. The definition of dose limiting toxicity (DLT) is based on the toxicity assessed at cycle 1 as follows: any grade 3−4 non hematological toxicity, ANC < 0.5 G/L lasting for 7 days or more, febrile neutropenia or thrombocytopenia <25 G/L. GCSF was not permitted as primary prophylaxis. Core biopsies were mandatory at baseline and after cycle 4. Pharmcokinetic (PK) samples were collected on day 1 of cycles 1 and 2. Results: To date, 18 pts with a median age of 53 years (range 36−65) have been enrolled at 5 Dose Levels (DLs). The toxicity profile for 18 patients (68 documented cycles) is summarized below. At DL5 (1000/100), 2 pts had DLTs (neutropenia grade 4 _7 days and febrile neutropenia), and 3 additional pts were enrolled with primary prophylactic G-CSF. As expected, the safety profile improved and the dose escalation will continue with prophylactic G-CSF to investigate DL6 (1250/100). These findings are consistent with published Phase I data for this combination [1]. N= 18 patients n (%) Grade 1 Grade 2 Grade 3 Grade 4 neutropenia 1 (6) 3 (17) 13 (72) febrile neutropenia 2 (11) fatigue 8 (44) 7 (39) diarrhoea 9 (50) 3 (17) pain: joint/muscle/other 5 (28)/4 (22)/3 (17) 4 (22)/4 (22)/3 (17) 0/0/1 (6) constipation 2 (11) 3 (17) 1 (6) elevated transaminases SGPT/SGOT 7 (39)/5 (28) Conclusions: The main toxicity of the L + D combination is haematological and was reached at DL5 (1000/100), without primary GCSF. An additional DL6 with primary prophylactic GCSF is being investigated (1250/100). PK data will be presented at the meeting plus the recommended dose for phase II studies.

Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update

Captopril, an orally active angiotensin-converting enzyme inhibitor, has been administered to 81 patients with different types of clinical hypertension. Most of the patients had previously uncontrollable high blood pressure. In order to achieve a satisfactory blood pressure control during long-term captopril therapy, a concomitant decrease in total body sodium was required in more than half of the patients. During our first two years of clinical experience with this new antihypertensive agent, side effects developed in 46.9 per cent of the patients and necessitated the withdrawal of the drug in 23.4 per cent of all patients. Only a few side effects such as hypotensive or syncopal episodes and cold extremities appeared to be due to the chronic blockade of the renin-angiotensin system. The most frequent and the most serious adverse reactions such as skin rash, altered taste, pancytopenia, and pemphigus foliaceus seemed to be specifically drug related. The incidence of cutaneous and taste problems was markedly higher in patients with impaired renal function in whom retention of captopril has been previously demonstrated. This suggests that the occurrence of adverse reactions to captopril could be lowered in the future by using smaller daily doses and by titrating them according to the renal function.